医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Orthocell’s ‘Cell Factory’ Granted Patent in US

2016年01月05日 PM11:00
このエントリーをはてなブックマークに追加


 

PERTH, Australia

Regenerative medicine company Orthocell Limited is pleased to announce issuance of a US patent relating to its cell factory technology which produces native cartilage and bone active proteins. This technology is one of the exciting pipeline products for the Company and supports the existing tendon and cartilage regeneration products that are currently marketed.

The intellectual property is based on research carried out by Orthocell director Professor Lars Lidgren, professor of orthopaedics at Lund University in Sweden. The department in Lund is a member of the International Society of Orthopaedic Centers group of world leading orthopaedic centres.

This innovative intellectual property is focused on the generation of ‘tissue specific’ growth factors for the regeneration of cartilage and bone and follows on from the Cell Factory work for the cartilage injuries that was announced by Orthocell in May 2015. Growth factors are an important stimulator of soft tissue and bone regeneration and have traditionally been extremely difficult to isolate from the “soup” of various growth factors and proteins that exist within the body.

Orthocell Managing Director Paul Anderson said: ”This is another important step in bringing value to Orthocell’s tissue regeneration portfolio for enhancing repair of bone, tendon and cartilage injuries.

More than 500,000 cartilage surgeries are undertaken in the US each year and the use of growth factors to prevent or augment a portion of these surgeries represents an attractive market opportunity for Orthocell.

“These cultivated growth factors have the potential to be a clinically important and cost effective procedure for the regeneration of articular cartilage of the knee and also other joints,” Mr Anderson said. “As the population ages and cartilage conditions become more prevalent, doctors and patients are seeking treatments to alleviate symptoms that affect mobility and quality of life.”

The new patent further strengthens Orthocell’s pipeline opportunities which are strongly complimentary to its current regenerative medicine approaches. The patent will expire in 2027.

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160105005459/en/

CONTACT

For more information, please contact:
General enquiries
Orthocell
Limited
Paul Anderson, (08) 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor
relations

Buchan Consulting
Ben Walsh, 02 9237 2801
bwalsh@buchanwe.com.au
or
Media
enquiries

Buchan Consulting
Gavin Lower, (03) 8866 1215 /
0414 796 726
glower@buchanwe.com.au

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease